VEEDA CLINICAL RESEARCH Unlisted Shares

Veeda Clinical Research Ltd. is one of India's leading contract research organisations (CROs) — a company that conducts clinical trials, bioequivalence studies, and pharmacokinetic research on behalf of pharmaceutical companies seeking regulatory approvals for their drugs. Veeda Clinical unlisted shares are available at best price through Valowth Capital, offering exposure to India's booming pharmaceutical services sector at the pre-IPO stage.

India is the world's pharmacy — producing 20% of the world's generic medicines by volume. Behind every generic drug approval lies a clinical trial, and Veeda Clinical Research is one of the primary partners that Indian and global pharma companies use to conduct these studies in India, where clinical trial costs are a fraction of Western rates.

Why Veeda Clinical Research unlisted shares are attracting pharma-sector investors:The global CRO market is growing at double-digit rates, driven by increasing pharmaceutical R&D spending, the complexity of modern clinical trials, and the outsourcing trend where pharma companies prefer to use specialist CROs rather than build in-house trial capabilities. India-based CROs offer a compelling value proposition: world-class scientific capabilities at significantly lower cost.

Veeda's specific strength in bioequivalence (BE) studies — the backbone of generic drug approvals globally — puts it at the centre of India's $50 billion generic pharma export industry. Every generic drug needs a BE study; Veeda does them.

Valowth Capital handles complete, verified demat-based transfer of Veeda Clinical Research unlisted shares with full KYC documentation.

Tax: LTCG (24+ months) = 20% with indexation. STCG = per income slab. No STT applicable.